211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome With Excess Blasts · Recurrent Acute Myeloid Leukemia · Refractory Acute Lymphoblastic Leukemia · Recurrent Acute Lymphoblastic Leukemia · Recurrent Mixed Phenotype Acute Leukemia · Refractory Acute Myeloid Leukemia · Refractory Mixed Phenotype Acute Leukemia · Mixed Phenotype Acute Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Study coordinator (Brenda M. Sandmaier) · bsandmai@fredhutch.org · 206-667-4961
Contact: Principal Investigator (Brenda M. Sandmaier)

Study leads

Brenda M. Sandmaier
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia in Remission

Abroad (travel likely)RecruitingPHASE1, PHASE2

Seattle, United States

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Acute Myeloid Leukemia · Accelerated Phase Chronic Myeloid Leukemia · Blast Phase Chronic Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Ghent, Belgium · Paris, France

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Hematologic Malignancy · Acute Leukemia · Remission

Abroad (travel likely)RecruitingPHASE2

Minneapolis, United States

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Duarte, United States